In vitro diagnostics company Theradiag (Paris:ALTER) on Monday announced that it achieved revenue of EUR10.4m for the year ended 31 December 2020.

This marks a growth of 8% when compared with the revenues of EUR9.6m in 2019 and in line with the company's strategic plan.

As of 31 December 2020, the company recorded net cash of EUR3.5m, including a PGE state-guaranteed loan of EUR1.9m, an improvement versus the net cash of EUR2.9m at 31 December 2019 and EUR1.7m at 30 June 2020.

The company announced excellent performance for Theranostics sales, with growth of 15.5%, substantial expansion in activity in the US, materialized by growth of 34.0% as well as solid performance for sales in France, driven by IVD activity.

On 22 March 2021, the company will disclose the FY 2020 results before market opens plus conduct its Annual General Meeting on 6 May 2021.